Like severe influenza, coronavirus disease-19 (COVID-19) resulting in acute respiratory
distress syndrome (ARDS) has emerged as an important disease that predisposes patients to …

Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has
been reported infrequently. The first resistant isolate was detected in 1999 in Manchester, …

Invasive fungal infections cause morbidity and mortality in severely ill patients, and limited
drug classes restrict treatment choices. The echinocandin drugs are the first new class of …

Fungal infections due to Candida and Aspergillus species cause extensive morbidity and
mortality, especially among immunosuppressed patients, and antifungal therapy is critical to …

Background. Fluconazole (FLC) resistance is common in C. glabrata and echinocandins are
often used as first-line therapy. Resistance to echinocandin therapy has been associated …

The recent global pandemic of COVID-19 has predisposed a relatively high number of patients
to acute respiratory distress syndrome (ARDS), which carries a risk of developing super-…

Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of
FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced …

All serious fungal infections need appropriate antifungal therapy for successful patient outcome.
Only a few classes of antifungal drugs are available, so the emergence of resistance to …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal drug …

Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health
care priority. Some analyses, including the O’Neill report, have predicted that deaths due …